SFI Health™ EMEA Announces the Launch in Portugal of Equazen® Food Supplements, the Brand Developed to Support Cognitive Needs
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, is excited to announce that Equazen® products will soon be available in Portugal. The company specializes in clinically researched products in microbiome, cognition, and well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250226258206/en/
Discover Equazen®, a science-based food supplement designed and studied to help nourish, enhance, and support the human brain’s potential across all life stages. (Graphic: Business Wire)
This marks a significant step forward in SFI Health™ EMEA's ongoing European expansion, following the exclusive license-in agreement signed in February 2024 with Eqyon Healthcare Solutions, a local distributor specialized in healthcare products. Under the terms of the agreement, Eqyon will use its sales and marketing expertise to distribute Equazen® range in pharmacies and parapharmacies.
Equazen® is a trusted global brand offering science-based nutritional solutions to support brain health and cognitive function. Equazen® products feature a unique combination of essential fatty acids (Omega 3 and Omega 6), proven in over 15 clinical studies to support learning, concentration, and healthy brain development.
Matthew Brabazon, GM of SFI Health™ EMEA commented: “We are excited to offer our science-backed Equazen® solutions to Portuguese consumers, who are becoming more proactive in supporting their cognitive needs. Our entry in Portugal is another step of our development plan to grow in the region by widening our partners network and customer base.”
Mr. Nuno Carvalho, CEO of Eqyon, added: “We believe Equazen® products will make a meaningful impact in our market, thanks to their high-quality ingredients and well-documented benefits. We are proud to bring Equazen® back to Portugal and will work closely with SFI Health™ EMEA to strengthen confidence in natural solutions among healthcare professionals and consumers."
Brain health supplements are one of the fastest growing segments in the global food supplements market: in Europe, between 2023 and 2030, the market is expected to grow at a compound annual rate of 12.5%, driven by increased awareness of cognitive and mental health.
SFI Health™ EMEA and Equazen® are present in several markets, including Spain, United Kingdom, Switzerland, Poland, Czech, Slovak, the Netherlands, the Nordics and the Baltics. The company aims at further widening Equazen® distribution to unlock the potential sales of the brand and make the most of the growing brain health supplements market.
About SFI Health™
SFI Health™ is a global leader in natural healthcare, specialized in the design, development and commercialization of clinically researched products in the areas of microbiome, cognition and wellbeing.
Guided by the belief in the healing potential of natural products, SFI Health™combines a rigorous pharma-based approach with the benefits of naturally sourced solutions.
An extensive network of trusted business partners enables the company, headquartered in Australia, to market its own brands, reaching consumers in over 50 countries. The EMEA SFI Health™ regional office in Lugano, Switzerland, manages commercial operations across Europe, Middle East and Africa.
SFI Health™ is committed to fostering confidence in natural healthcare by sharing state-of-the-art research, technical expertise and comprehensive sales & marketing resources with consumers, healthcare professionals and partners worldwide.
For more information go to sfihealth.com or follow us SFI Health on LinkedIn.
About Eqyon Healthcare Solutions
Eqyon Healthcare Solutions is a customer-focused company dedicated to optimizing healthcare supply chains. By leveraging strategic partnerships and innovative solutions, we help healthcare providers, pharmacies, and institutions improve efficiency, reduce costs, and enhance patient care.
We are committed to addressing the challenges within the healthcare sector through effective, evidence-based solutions. As part of this commitment, we are excited to reintroduce Equazen® to the Portuguese market. Equazen® aligns with our mission to offer natural, scientifically-backed products that promote cognitive health and well-being. In partnership with trusted global brands like Equazen®, we expand access to high-quality, proven solutions that improve lives.
At Eqyon Healthcare Solutions, we aim to be a leading provider of efficient healthcare solutions, continuously transforming challenges into opportunities and ensuring excellence in customer care.
For more information, visit eqyon.eu and follow Eqyon Healthcare Solutions on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250226258206/en/
Contacts
For more information
SFI Health™ EMEA
Elisabetta Bianchi
e-mail address: elisabetta.bianchi@sfihealth.com
Eqyon
Nuno Carvalho & CEO
e-mail address: nuno.carvalho@eqyon.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 13:50:00 EEST | Press release
SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &
Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 11:00:00 EEST | Press release
Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts25.4.2025 10:28:00 EEST | Press release
Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged to apply for Plan A. Relevant fields include computer science, software engineering, artificial intelligence, cybersecurity, information and telecommunication engineering, mathematics, statistics, and other emerging interdisciplinary areas. To better foster the development of technological innovators in this new AI era, Plan A offers candidates comprehensive support and resources, including unrestricted access to AI hardware and tailored career paths that allow for significant research freedom. Ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom